Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed’s HS-001 investigational cell therapy as its first in-human trial commences

Posted on by

NOTTINGHAM, England, March 14, 2023 /PRNewswire/ — Albumedix Ltd (‘Albumedix’), Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc (‘Heartseed’), Tokyo, Japan, Tuesday 14th March 2023, announce that Recombumin® is a critical component of…